New antiretroviral therapy

New antiretroviral therapies (ARTs) are being developed to improve the treatment of HIV infection. Here are some recent advancements:

1. Bictegravir (BIC): A new integrase inhibitor approved by the FDA in 2018. BIC is a once-daily pill that has shown high efficacy and a favorable safety profile.
2. Cabotegravir (CAB): A long-acting injectable integrase inhibitor approved by the FDA in 2018. CAB is administered every 8 weeks and has shown high efficacy and a favorable safety profile.
3. Dolutegravir (DTG): A second-generation integrase inhibitor that has been shown to be highly effective and well-tolerated. DTG is available as a once-daily pill.
4. Raltegravir (RAL): A first-generation integrase inhibitor that has been shown to be effective and well-tolerated. RAL is available as a twice-daily pill.
5. BMS-986139: A new integrase inhibitor in Phase III clinical trials. It has shown high efficacy and a favorable safety profile.
6. GSK744: A new integrase inhibitor in Phase III clinical trials. It has shown high efficacy and a favorable safety profile.
7. Lamivudine (3TC): A new nucleoside reverse transcriptase inhibitor (NRTI) that has been shown to be effective and well-tolerated. 3TC is available as a once-daily pill.
8. Tenofovir alafenamide (TAF): A new NRTI that has been shown to be effective and well-tolerated. TAF is available as a once-daily pill.
9. Elvitegravir (EVG): A new integrase inhibitor that has been shown to be effective and well-tolerated. EVG is available as a once-daily pill.
10. Ibalizumab (IBA): A new monoclonal antibody that has been shown to be effective and well-tolerated. IBA is administered every 2 weeks.

These new ARTs offer several advantages, including:

• Improved efficacy: Many of these new ARTs have shown higher efficacy rates than older treatments.
• Simplified regimens: Some of these new ARTs are available as once-daily pills or have simplified dosing schedules.
• Reduced side effects: Some of these new ARTs have shown reduced side effects compared to older treatments.
• Increased options: The availability of new ARTs provides more treatment options for people living with HIV.

It's important to note that the development of new ARTs is an ongoing process, and new treatments are being studied and approved regularly.